Exelixis, Inc. EXEL today announced positive overall survival
(OS) results from coBRIM, the phase 3 pivotal trial evaluating
cobimetinib, a specific MEK inhibitor discovered by Exelixis, in
combination with vemurafenib in previously untreated patients with
unresectable locally advanced or metastatic melanoma carrying a BRAF
V600 mutation. Exelixis' collaborator Genentech, a member of the Roche
Group, informed the company that coBRIM met its secondary endpoint of
demonstrating a statistically significant and clinically meaningful
increase in overall survival for patients receiving the combination of
cobimetinib and vemurafenib, as compared to vemurafenib monotherapy.
Ongoing study monitoring did not identify any new safety signals.
Long-term safety data are expected later this year. These data will be
the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in